GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (HKSE:02269) » Definitions » PE Ratio

WuXi Biologics (Cayman) (HKSE:02269) PE Ratio

: 15.46 (As of Today)
View and export this data going back to 2017. Start your Free Trial

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-04-23), WuXi Biologics (Cayman)'s share price is HK$13.02. WuXi Biologics (Cayman)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was HK$0.84. Therefore, WuXi Biologics (Cayman)'s PE Ratio for today is 15.46.

Good Sign:

WuXi Biologics (Cayman) Inc stock PE Ratio (=11.19) is close to 10-year low of 11.19


The historical rank and industry rank for WuXi Biologics (Cayman)'s PE Ratio or its related term are showing as below:

HKSE:02269' s PE Ratio Range Over the Past 10 Years
Min: 11.19   Med: 150.79   Max: 366.67
Current: 15.46


During the past 10 years, the highest PE Ratio of WuXi Biologics (Cayman) was 366.67. The lowest was 11.19. And the median was 150.79.


HKSE:02269's PE Ratio is ranked better than
75.5% of 249 companies
in the Biotechnology industry
Industry Median: 27.29 vs HKSE:02269: 15.46

WuXi Biologics (Cayman)'s Earnings per Share (Diluted) for the six months ended in Jun. 2023 was HK$0.57. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was HK$0.84.

As of today (2024-04-23), WuXi Biologics (Cayman)'s share price is HK$13.02. WuXi Biologics (Cayman)'s EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 was HK$0.99. Therefore, WuXi Biologics (Cayman)'s PE Ratio without NRI for today is 13.18.

During the past 10 years, WuXi Biologics (Cayman)'s highest PE Ratio without NRI was 292.80. The lowest was 10.00. And the median was 122.89.

WuXi Biologics (Cayman)'s EPS without NRI for the six months ended in Jun. 2023 was HK$0.71. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 was HK$0.99.

During the past 12 months, WuXi Biologics (Cayman)'s average EPS without NRI Growth Rate was 4.70% per year. During the past 3 years, the average EPS without NRI Growth Rate was 55.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 55.70% per year.

During the past 10 years, WuXi Biologics (Cayman)'s highest 3-Year average EPS without NRI Growth Rate was 138.10% per year. The lowest was 49.30% per year. And the median was 59.60% per year.

WuXi Biologics (Cayman)'s EPS (Basic) for the six months ended in Jun. 2023 was HK$0.60. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was HK$0.90.


WuXi Biologics (Cayman) PE Ratio Historical Data

The historical data trend for WuXi Biologics (Cayman)'s PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 118.27 215.19 98.14 53.06 35.15

WuXi Biologics (Cayman) Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 98.14 At Loss 53.06 At Loss At Loss

Competitive Comparison

For the Biotechnology subindustry, WuXi Biologics (Cayman)'s PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WuXi Biologics (Cayman) PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s PE Ratio distribution charts can be found below:

* The bar in red indicates where WuXi Biologics (Cayman)'s PE Ratio falls into.



WuXi Biologics (Cayman) PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

WuXi Biologics (Cayman)'s PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=13.02/0.842
=15.46

WuXi Biologics (Cayman)'s Share Price of today is HK$13.02.
For company reported semi-annually, WuXi Biologics (Cayman)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.84.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio or PE Ratio (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


WuXi Biologics (Cayman)  (HKSE:02269) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


WuXi Biologics (Cayman) PE Ratio Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi Biologics (Cayman) (HKSE:02269) Business Description

Address
No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.

WuXi Biologics (Cayman) (HKSE:02269) Headlines

No Headlines